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journal homepage: www.jfma-onl ine.comLETTER TO THE EDITORReply to comment on: Is the renoprotective
effect of erythropoietin in chronic kidney
disease a myth?Dear Editor
In their Letter to the Editor,1 Rafieian-Kopaei and Nasri
respond to our paper2 in which we reviewed current clinical
and laboratory evidence of the renoprotective potential
of recombinant erythropoietin (EPO) in chronic kidney dis-
ease (CKD). Based on the lack of confirmatory evidence on
the application of EPO treatment for renoprotection earlier
than that for erythropoiesis, we suggest further clinical
studies are necessary to define when to start EPO treat-
ment and what the optimal EPO dosage is for slowing CKD
progression.
In addition to the limited clinical evidence of the reno-
protective effect of EPO in CKD patients,2 we recognize the
laboratory evidence that EPO protects against kidney
damage in a variety of animal models, including the model
induced by gentamicin reported by Rafieian-Kopaei et al.1
However the fundamental question raised in our paper for
the renoprotective effect of EPO in kidney disease is no
functional EPO receptor (EPOR) in the kidney.3 Previous
laboratory evidence suggests that the tissue protective
effect of EPO is mediated via a heterocomplex composed of
EPOR and b common receptor (bcR; also known as CD131).
Given the fact that the kidney has no functional EPOR and
the tissue protective effect needs a EPORebcR hetero-
complex for signal transduction, how could we expect a
biological effect of EPO on kidney?
A better understanding of the mechanisms underlying
the renoprotective effect observed in both clinical and
laboratory studies will be of great help to develop novel
treatment in the future. Carbamylated EPO, an EPO de-
rivative without EPOR affinity, has the same tissue-
protective, but not erythropoietic effect as EPO, and both
carbamylated EPO and EPO lose their protective effect inDOI of original article: http://dx.doi.org/10.1016/
j.jfma.2013.05.006.
0929-6646/$ - see front matter Copyright ª 2013, Elsevier Taiwan LLC
http://dx.doi.org/10.1016/j.jfma.2013.05.005bcR knockout mice, indicating that bcR, and not EPOR, is
indispensable for mediating the tissue-protective effect. In
addition to conducting clinical studies to define the optimal
timing and dosage for slowing CKD progression, it is also
necessary to study which renal cells posses the receptors
reacted by EPO and whether EPO protects renal tubular
epithelial cells directly or through modulating the function
of the other renal cells.
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